Eliot Forster - 14 Sep 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Director
Signature
/s/ Eyal Rubin, POA
Issuer symbol
PLX
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
4
Filing time
15 Sep 2023, 16:46:57 UTC
Previous filing
09 Mar 2023
Next filing
04 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Options (Right to Buy) Award $0 +85,715 $0.000000 85,715 14 Sep 2023 Common Stock 85,715 $1.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.